US Patent Issued to Procella Therapeutics on Sept. 2 for "Use of neuropilin-1 (NRP1) as a cell surface marker for isolating human cardiac ventricular progenitor cells" (Swedish, American Inventors)

ALEXANDRIA, Va., Sept. 3 -- United States Patent no. 12,404,488, issued on Sept. 2, was assigned to Procella Therapeutics AB (Tullinge, Sweden).

"Use of neuropilin-1 (NRP1) as a cell surface marker for isolating human cardiac ventricular progenitor cells" was invented by Kenneth R. Chien (Cambridge, Mass.), Jonathan Clarke (Stockholm) and Chuen Yan Leung (Stockholm).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides NRP1 as a cell surface marker for isolating human cardiomyogenic ventricular progenitor cells (HVPs), in particular progenitor cells that preferentially differentiate into cardiac ventricular muscle cells. Additional HVP cell surface markers identified by single cell seq...